A double-blind placebo-controlled, randomized pilot study: [EpiCor®] has beneficial effects on erythrocyte health and mucosal immune protection in healthy subjects – Source: Open Nutrition Journal, 2008

[Note: To read the full text of this open access article, click here.]

This double-blind, randomized, placebo-controlled pilot study was designed to evaluate effects of consumption of an antioxidant-rich, yeast culture-based high-metabolite immunogen EpiCor®. [An immunogen is a substance that supports immunity when introduced into the body.]

Twenty-five healthy participants consumed 0.5 gram EpiCor® or placebo daily for 5 weeks. The hematocrit [number and size of red blood cells] increased significantly in the EpiCor® group (p < 0.04).

A mild increase in saliva sIgA upon EpiCor® consumption (p=0.16) prompted a subsequent 8-week open-label study involving 22 people showing significant increase in sIgA (p < 0.05).

EpiCor® consumption led to a mild increase in serum IL-10 (p < 0.2); no other differences in Th1/Th2 cytokines were observed. [IL-10 is an anti-inflammatory signaling cytokine.]

Minor health complaints decreased in the EpiCor® group compared to the placebo group (p < 0.02).

Seasonal allergies increased in the placebo group, but were not observed in the EpiCor® group; this was reflected by increased serum IgE in the placebo group compared to the EpiCor® group (p < 0.13). [IgE is an antibody marker of allergic reaction.]

We conclude that consumption of EpiCor® supported the health of red blood cells and mucosal immune protection.

Source: Open Nutrition Journal, 2008 vol 2 (8) pp. 68-75 doi: 10.2174/1874288200802010068, by Jensen GS, Patterson KM, Barnes J, Schauss AG, Beaman R, Reeves SG, Robinson LE. NIS Research Labs and Beaman’s Wellness Center, Klamath Falls, Oregon; AIBMR Life Sciences, Puyallup, Washington; Embria Health Sciences, Ankenny, Iowa, USA. [E-mail: gitte@holgernis.com ]

1 Star2 Stars3 Stars4 Stars5 Stars (15 votes, average: 3.05 out of 5)
Loading...



Leave a Reply